Cancer

Title
The Study of an Oral Medication in Patients with Metastatic Renal Cell Cancer
Trial Number
204778101712
Number of Participants
180
Principal Investigator

Joseph Clark

M.D.
Hematology/Oncology
Professor
Eligibility

The patient must be 18 years or older and must have pathologically confirmed renal cell carcinoma with a clear cell component. Pure papillary and chromophobe histologies are excluded. There must be pathologic confirmation of metastatic disease in the resected metastatectomy specimen. Patient must have undergone nephrectomy or partial nephrectomy to remove primary renal cell carcinoma (at any time in the past). Patient must have undergone surgical resection to remove one or more sites of metastatic disease, with successful removal of all known sites 2-12 weeks prior to randomization. Eligible patient must have no evidence of disease on post-operative imaging (CT and/or MRI) conducted within four weeks prior to randomization. Patient must not have received any prior or concurrent systemic therapy for RCC. Adjuvant placebo administration is permitted. Patient must have an ECOG performance status of 0 or 1 at the time of randomization.

Purpose

The purpose of this study is to determine whether taking an oral drug known as pazopanib will reduce the risk of the cancer recurring in the future.

Enrollment

(708) 327-3221

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.